What strategy will WHO take to provide 2 billion doses of vaccine to high-risk groups around the world?

26, the World Health Organization (WHO) announced that the outbreak of Ebola in the Republic of Congo has officially endedHowever, according to Johns Hopkins University, nearly 10 million people worldwide are infected with the new coronavirusThe new crown epidemic not only poses a serious threat to the health of people around the world, but also has a significant impact on the world economyAccording to international monetary fund estimates, the new crown outbreak will have a $325 billion impact on the global economy every monthto accelerate the development, production, and distribution of diagnosis, therapy and vaccines for COVID-19, the World Health Organization launched the Access COVID-19 Tool Acceleration Program (Access COVID-19 Accelerator, ACT Accelerator) in April this year with a number of national and non-profit organizationsOn the 27th, WHO released details of the accelerated planAs one of the four pillars of the accelerated programme, WHO will work with partners to accelerate vaccine development, production, and equitable distribution of the new coronavirusTheir goal is to provide 2 billion doses of safe and effective new coronavirus vaccine to high-risk populations around the world by the end of 2021! Let's take a look at what strategies they will adopt to achieve this ambitious goalpooled global resources to support the development of a variety of different vaccines and share the fruits of successfulaccording to the World Health Organization, there are currently more than 100 new coronavirus vaccine research and development projects worldwide, 16 of which have entered the clinical trial phaseHowever, developing a safe and effective vaccine is still not easyThe history of vaccine development shows that most early vaccines will not ultimately succeed, and the ultimate success rate of early vaccines is less than 20% before Phase 2 clinical trialsand in the context of a pandemic, the expansion of vaccine production needs to be carried out in parallel with human clinical trials, which means that there is a considerable risk of expanding production and the potential for significant investment in the expansion of the resulting candidate vaccine to fail in clinical trialsSo how can this risk be reduced for every country that urgently needs an effective vaccine to stem the spread of the new crown epidemic?the best chance for each country to succeed lies in pooling resources to support a research and development pipeline (vaccine portfolio) with a variety of different vaccine candidatesThis increases the chances of success and the opportunity to share the fruits of success after a particular vaccine has been successfulFor countries with the ability to develop and produce vaccines locally, supporting the Vaccine Development Pipeline may help them reduce the risk of failure to develop their own candidate vaccines multiple tools to promote vaccine development, production and regulatory processes
for vaccine development, even if clinical trials are successful, who estimates that the vaccine's production capacity is unlikely to exceed demand in the next 18 months Therefore, expanding vaccine production capacity is one of the most challenging aspects of vaccine development THE VACCINE COMPONENT OF THE ACT ACCELERATOR (COVAX) WILL BUILD ON THE ORGANIZATIONAL FRAMEWORK AND EXPERTISE OF WHO, THE ALLIANCE FOR THE INNOVATION IN EPIDEMIOLOGY PREVENTION (CEPI) AND THE GLOBAL ALLIANCE FOR VACCINE IMMUNIZATION (GAVI) Stimulating the expansion of vaccine production capacity needs to be done in two ways: on the one hand, through advance market commitments to stimulate research and development and production institutions to expand production capacity before the approval of the new crown vaccine, and on the other hand, to raise funds to help research and development institutions take risks and invest in vaccine research and development, production capacity and inventory COVAX will bring together CEPI's expertise in supporting vaccine development, GAVI's ability to purchase and distribute vaccines, and WHO's optimization of regulatory approvals and support for vaccine distribution to ensure that vaccines can now be produced on a large scale Fair and equitable distribution of vaccines even if the candidate vaccine is successful in clinical trials, the initial expansion phase of the vaccine will remain in short supply, which will face a major challenge in the distribution of the vaccine COVAX's vaccine distribution method will be based on the principle of reducing mortality and protecting health care systems, and the initial vaccine will be assigned to priority populations These priority groups may include: workers in the health care system (1 percent of the global population) adults over 65 (8 percent of the global population) other high-risk adults with underlying diseases (including hypertension, diabetes, etc.) when vaccines are limited, COVAX will distribute vaccines fairly and fairly based on ethical values and public health objectives to ensure that every country that supports the project has access to a portion of the vaccine Early access to the new crown requires support and solidarity around the world
if adequatefunded, COVAX will immediately sign up-to-do agreements to purchase 5-10 candidate vaccines that meet specific technical standards The goal is to buy a total of 2 billion doses of vaccine by 2021 It will buy as many vaccines as possible from each vaccine manufacturer, so that it can obtain the largest number of vaccines at the most economical price It will also cover the costs of vaccine manufacturers risking capacity and inventory before the vaccine's effectiveness is determined requires significant up-front funding to accomplish these tasks, it said in a press release today that it will require $18.1 billion in up-front investment, and that it has received a total of $3.4 billion in contributions from governments, companies and agencies around the world since the launch of the Access to COVID-19 Tool Acceleration Program Tomorrow, the European Union and Global Citizen will hold a joint summit and fund-raising campaign in support of the Access to COVID-19 Tool Acceleration Program, calling on people around the world to work towards making COVID-19 accessible to everyone in every country in the world "Vaccines, testing and therapies are all key tools to defeat COVID-19, but another necessary element is needed to make these tools work," World Health Organization Director-General Dr Tande-seok said at a news conference today "
.